About Second Genome
Second Genome was a Healthcare company based in San Francisco (United States) founded in 2009. Second Genome develops innovative microbiome-based technologies for personalized medicine in various health disorders. It operates on a B2B model. Second Genome has raised $63.7 million across 6 funding rounds from investors including HHS, SR One and Advanced Technology Ventures. The company has 37 employees. The company is recorded as dissolved. Its focus areas include Biotechnology, Personalized Medicine and Microbiome Technologies. Its legal entity is SECOND GENOME, INC. Its competitors include GSK, Avidity Biosciences, Nimbus Therapeutics, Escient Pharmaceuticals and Kriya Therapeutics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Second Genome, established in 2009 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, personalized medicine, and microbiome technologies. Second Genome develops innovative microbiome-based technologies for personalized medicine in various health disorders. Adapting to market demands with innovation and client-focused strategies.
- Headquarters San Francisco, United States
- Employees 37
- SectorsHealthcare
- Website secondgenome.com
- Social X
- Legal Name Second Genome, Inc.
- Total Equity Funding$63.7M (USD)
in 6 rounds
- Latest Funding Round$2.09M (USD), Grant
Jul 2017
- InvestorsHHS
& 12 more
- Employee Count37
Funding Insights of Second Genome
Second Genome has successfully raised a total of $63.7M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.09 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $63.7M
- Total Rounds 6
- Last Round Grant — $2.09M
- First Round $1.2M
(Jun 2010)
- Investors Count 13
All 6 funding rounds of Second Genome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $2.09M | Grant | – | – | |
| Jul 2016 | $8.4M | Series B | – | SR One | – |
| Apr 2016 | $42.6M | Series B | – | Roche, Pfizer Venture Investments | |
| Jun 2013 | $6.5M | Series A | – | Advanced Technology Ventures, Morgenthaler | – |
| Aug 2011 | $5M | Series A | – | Advanced Technology Ventures, Morgenthaler | |
| Jun 2010 | $1.2M | Seed | – | – |
13 investors in total: 12 institutional and 1 angel.
Investors in Second Genome
Second Genome has secured backing from 13 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, SR One and Advanced Technology Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
VC firm making investment in early stage startups in the US | – | atvcapital.com | Menlo Park, United States | |
Venture capital and private equity investment firm | – | morgenthaler.com | Portola Valley, United States | |
VC firm investing in seed and early stage companies in the US | – | seraphgroup.net | Tampa, United States | |
Digitalis Ventures is engaged in health-focused investments. | – | digitalisventures.com | New York, United States | |
Corporate-backed venture capital firm focused on the healthcare sector | – | roche.com/venturefund.htm | - | |
Venture capital is focused on healthcare by Pfizer's investment arm. | – | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | |
Venture capital firm focused on healthcare startups | – | lifeforcecap.com | San Francisco, United States | |
Healthcare startups are accelerated by Mayo Clinic Business Accelerator. | – | mcbusaccel.com | Rochester, United States | |
TradeMO is recognized as an innovative payment processing platform. | – | wavepointventures.com | Russian Federation |
Investor details for Second Genome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Second Genome
13 people are tracked at Second Genome (2 in leadership, 9 in board & advisors, 2 in team); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Satish Viswanatham | Sr. Director of Engineering | Leadership |
Pete Roddy | CFO Advisor | Leadership |
Mike Carusi | Board Member | Board & advisors |
Carol Nuechterlein | Board Member | Board & advisors |
Reinhard Dummer | Advisor | Board & advisors |
Jerrold M. Olefsky | Advisor | Board & advisors |
Arun Sanyal | Advisor | Board & advisors |
R. Balfour Sartor | Advisor | Board & advisors |
Corey Goodman | Co-Founder & Chair | Board & advisors |
Barbara J. Dalton | Board Member | Board & advisors |
Jason Lettmann | Board Member | Board & advisors |
Richard Grey | Cloud System Administrator | Team |
Laura Brege | Senior Advisor | Team |
Complete people profiles for Second Genome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Second Genome
3 dated milestones of Second Genome across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Second Genome is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $2.1M.
Competitors of Second Genome
Second Genome has 9 listed competitors in our database, 8 of them funded. They include GSK, Avidity Biosciences, Nimbus Therapeutics, Escient Pharmaceuticals and Kriya Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders |
Detailed competitors of Second Genome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as Second Genome (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Second Genome
Complete news archive for Second Genome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Second Genome
Second Genome was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Second Genome is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Second Genome is a funded company, having raised a total of $63.7M across 6 funding rounds to date. The company's 1st funding round was a Seed of $1.2M, raised on Jun 2010.
Second Genome has 37 employees.
Second Genome, established in 2009 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, personalized medicine, and microbiome technologies. Second Genome develops innovative microbiome-based technologies for personalized medicine in various health disorders. Adapting to market demands with innovation and client-focused strategies.
Second Genome's top competitors include Sutro Biopharma, Escient Pharmaceuticals and Nimbus Therapeutics.
Second Genome has 13 investors. Key investors include HHS, SR One, Advanced Technology Ventures, Morgenthaler, and Seraph Group.
Second Genome operates through Second Genome, Inc..